Vivimed Labs in the limelight

Vivimed Labs is most certainly the “star” on the bourses today. The counter is showing some tremendous amount of volumes and the stock price has spurted up 10% to over Rs.101. Its 52-week high stands at Rs.121.15.

The reason for this joy on the counter is twofold – firstly, its FDF (finished dosage formulations) manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection.

Secondly, it has obtained ANDA (abbreviated new drug application) approval for Metronidazole and same is commercialized. The company went on to add that it had got the ANDA for Zolpidem and this is expected to be commercialised by Q4 FY17.

In the given Press Release, the company has said that Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expects one more filing to be completed by Q4 FY2017. These products provide vertical integration with the in-house APls.